Angelini Pharma acquires Catalyst Pharmaceuticals

Angelini Pharma is acquiring U.S.-based Catalyst Pharmaceuticals in a transaction valued at over $4.1 billion. The acquisition represents a strategic move by the Italian company into the U.S. market, focusing on rare neuromuscular and neurological diseases. This move is poised to accelerate Angelini's transformation from a Europe-centric entity into a significant global player in the central nervous system (CNS) rare-disease sector.

The agreement terms stipulate that Angelini will pay $31.50 per share in cash for Catalyst, marking a 21% premium over the company's closing share price on April 22, 2026, and a 28% premium to its 30-day volume-weighted average price. The deal has received unanimous approval from both companies' boards and is expected to close in the third quarter of 2026. Completion is contingent on Catalyst stockholder approval and standard regulatory reviews. BNP Paribas will coordinate and underwrite the financial package, which will be a mix of cash and debt, with contributions from Blackstone funds and select international partners.

Catalyst's addition to Angelini brings three FDA-approved products for rare conditions, including Firdapse for Lambert-Eaton myasthenic syndrome, Agamree for Duchenne muscular dystrophy, and Fycompa, an antiepileptic medication. Catalyst CEO Rich Daly highlighted the merger's potential to enhance therapeutic accessibility globally and deliver immediate cash value to shareholders.

This acquisition significantly impacts Angelini's strategy by providing a substantial U.S. commercial foothold. With over a century of history, Angelini has shifted focus in recent years towards CNS ailments, investing in pipeline developments and partnerships. This transaction aligns with its strategic objectives, offering operational synergy and platform expansion potential in the rare disease space.

The move reflects broader industry dynamics, where pharmaceutical companies seek to bolster pipelines through targeted acquisitions amid increasing competition in biopharma. For Angelini, securing a U.S. footprint in rare diseases could enhance its competitive positioning against peers also eying CNS pathways. As the deal progresses, regulatory scrutiny and stakeholders' response will be critical to its successful fruition, with key upcoming milestones including shareholder and regulatory approvals.